NCT05238441 is a Phase 2 clinical trial of SCTV01E in COVID-19, sponsored by Sinocelltech Ltd..

Who is sponsoring NCT05238441?

NCT05238441 is sponsored by Sinocelltech Ltd..

What drugs are being tested in NCT05238441?

Interventions in NCT05238441: SCTV01E, Comirnaty, SCTV01E, Comirnaty.

What condition does NCT05238441 study?

NCT05238441 studies COVID-19, Sars-CoV-2 Infection.

Is NCT05238441 still recruiting?

NCT05238441 is currently status unknown. Last updated 2 March 2022.

Last reviewed 2022-03-02 · How we verify

NCT05238441

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

Status unknown Phase 2 Last updated 2 March 2022

What this trial tests

Phase 2 trial testing SCTV01E in COVID-19 in 360 participants. Status unknown.

Timeline

20 March 2022

Primary endpoint
1 June 2022

1 May 2023

Quick facts

Lead sponsor	Sinocelltech Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	360
Start date	20 March 2022
Primary completion	1 June 2022
Estimated completion	1 May 2023

Drugs / interventions tested

SCTV01E — full drug profile →
Comirnaty (BNT162b2 (tozinameran)) — full drug profile →
SCTV01E — full drug profile →
Comirnaty (BNT162b2 (tozinameran)) — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Sars-CoV-2 Infection — all drugs for Sars-CoV-2 Infection →

Sponsor

Sinocelltech Ltd. — full company profile →

Who can join

18 and older, any sex, with COVID-19 or Sars-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the immunogenicity and safety of SCTV01E in participants aged ≥18 years and previously fully immunized with mRNA COVID-19 vaccine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

COVID-19 vaccine development: milestones, lessons and prospects.
Li M, Wang H, Tian L, Pang Z, et al · · 2022 · cited 298× · PMID 35504917 · DOI 10.1038/s41392-022-00996-y
OMICRON: Virology, immunopathogenesis, and laboratory diagnosis.
Bazargan M, Elahi R, Esmaeilzadeh A. · · 2022 · cited 41× · PMID 35726542 · DOI 10.1002/jgm.3435

Verify or expand the search:

Other trials of SCTV01E

Trials testing the same drug.

NCT05933512 — A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines · Phase 2 · unknown
NCT05683561 — A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People · Phase 3 · unknown
NCT05652543 — A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine · Phase 2 · completed
NCT05329051 — A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years · Phase 2 · unknown
NCT05345873 — A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Populat · Phase 2 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Sinocelltech Ltd. trials

Trials by the same sponsor.

NCT07244510 — Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa · Phase 2 · not yet recruiting
NCT07077252 — Phase I/II Study of SCTB39G in Advanced Solid Tumours · Phase 1, PHASE2 · not yet recruiting
NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06769984 — A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. · Phase 1, PHASE2 · not yet recruiting
NCT06801509 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05238441 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinocelltech Ltd.
Last refreshed: 2 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05238441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing